Ziopharm is developing the next generation of immuno-oncology medicines that target multiple types of cancers on two fronts — weaponizing the existing immune system and introducing new immune system elements. In addition, the company is  targeting the cost and complexity of these therapies. We worked with Ziopharm to build a brand around this dual approach and to illustrate how the company’s technology works to combat cancer.